Best scenario : trading halted to announce a JV coupled with uplist.
The shorters HAVE to cover their positions when it moves to a different exchange, and shareholders would be setting the cost for them to do so.. I've said it before, this could create an exponential explosion in pps far beyond what the science alone warrants (at this stage).. ACTC may be playing a risky game, but so are the shorters..
On the other hand, we could be looking at a reorganization via Chapter 11, in which case we shareholders will be royally screwed.
I continue to be very concerned at the silence from ACTC management in the face of such heavy shareholder concern, and the lack of contract renewal for Lanza..
Also consider that much of this uncertainty may be being driven by large pharma (indirectly of course).. they are not interested in cures, only treatments, so this science could be perceived as a threat to them, and they react accordingly..
